VISTAGEN THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $4.10 million for the 12-month period ending 2026-03-31, per its 10-K filed 2026-06-15.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-06-15
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-06-30 was $800.00K, a 20.00% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-03-31 was $900.00K, a 80.00% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2024-12-31 was $1.10M, a 83.33% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2024-09-30 was $1.00M, a 25.00% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2026 was $4.10M, a 2.50% increase from fiscal 2025.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $4.00M, a 73.91% increase from fiscal 2024.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $2.30M, a 34.29% decline from fiscal 2023.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $3.50M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2026-03-31 | $4.10M 10-K · filed 2026-06-15 | |||
| 2025-06-30 | $800.00K 10-Q · filed 2025-08-07 | $1.70M derived: sum of 2 quarters · filed 2026-06-15 | $2.80M derived: sum of 3 quarters · filed 2026-06-15 | $3.80M derived: sum of 4 quarters · filed 2026-06-15 |
| 2025-03-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-15 | $2.00M derived: sum of 2 quarters · filed 2026-06-15 | $3.00M derived: sum of 3 quarters · filed 2026-06-15 | $4.00M 10-K · filed 2026-06-15 |
| 2024-12-31 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-13 | $2.10M derived: sum of 2 quarters · filed 2025-02-13 | $3.10M 10-Q · filed 2025-02-13 | $3.60M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-09-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | $2.00M 10-Q · filed 2024-11-07 | $2.50M derived: sum of 3 quarters · filed 2025-08-07 | $3.10M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-06-30 | $1.00M 10-Q · filed 2025-08-07 | $1.50M derived: sum of 2 quarters · filed 2025-08-07 | $2.10M derived: sum of 3 quarters · filed 2025-08-07 | $2.90M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-17 | $1.10M derived: sum of 2 quarters · filed 2025-06-17 | $1.90M derived: sum of 3 quarters · filed 2025-06-17 | $2.30M 10-K · filed 2025-06-17 |
| 2023-12-31 | $600.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-13 | $1.40M derived: sum of 2 quarters · filed 2025-02-13 | $1.80M 10-Q · filed 2025-02-13 | |
| 2023-09-30 | $800.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | $1.20M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $400.00K 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | $3.50M 10-K · filed 2024-06-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |